UTRECHT, The Netherlands and CAMBRIDGE, MA, USA I 30, 2024 I Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology ...
PLANEGG-MARTINSRIED, Germany I 30, 2024 I Formycon AG (FSE: FYB, “Formycon”) and its commercialization partner Fresenius Kabi jointly announce that ...
PARIS, France I 30, 2024 I Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO), a clinical-stage biotechnology company leading the way in the ...
HANGZHOU, China I 30, 2024 I Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative ...
I Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for rare and common cardiovascular ...
Reported cumulative MMR rate of 44% (8/18) by 24 weeks, with stable or deepening responses between weeks 12 and 24, which continues to compare favorably to precedent Phase 1 trials of approved ...
Sage Therapeutics Announces Discontinuation of the Collaboration with Biogen on the SAGE-324 Program
Sage and Biogen will continue to partner on ZURZUVAE®, the first and only FDA-approved oral treatment for women with postpartum depression CAMBRIDGE, MA, USA I September 26, 2024 I Sage Therapeutics, ...
PLANEGG-MARTINSRIED, Germany I September 27, 2024 I Formycon AG (FSE: FYB, “Formycon”) and its commercialization partner Fresenius Kabi jointly announce that ...
BERLIN, Germany & CAMBRIDGE, MA, USA I September 27, 2024 I Bayer AG and BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned independently operated subsidiary of Bayer AG ...
PARIS, France and TARRYTOWN, NY, USA I7, 2024 I The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on ...
NORTH CHICAGO, IL, USA I6, 2024 I AbbVie (NYSE: ABBV) today announced positive topline results from its pivotal Phase 3 TEMPO-1 trial for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback